CA2318008A1 - Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound - Google Patents
Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound Download PDFInfo
- Publication number
- CA2318008A1 CA2318008A1 CA002318008A CA2318008A CA2318008A1 CA 2318008 A1 CA2318008 A1 CA 2318008A1 CA 002318008 A CA002318008 A CA 002318008A CA 2318008 A CA2318008 A CA 2318008A CA 2318008 A1 CA2318008 A1 CA 2318008A1
- Authority
- CA
- Canada
- Prior art keywords
- inert
- water
- alkaline
- alkaline polymer
- modified release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
The pharmaceutical formulation consists of a number of pellets that comprise a inert nucleus, a layer with the active ingredient, one or more intermediate layers that comprise at least a system of modified release, and an external layer of enteric coating.
These pellets can be obtained applying the different layers by means of fluid bed coating techniques using aqueous solutions or suspensions of the components of such layers. The pharmaceutical formulations can be hard gelatine capsules or tablets and are suitable for use in the prevention and treatment of disorders related to abnormal gastric acid secretion.
These pellets can be obtained applying the different layers by means of fluid bed coating techniques using aqueous solutions or suspensions of the components of such layers. The pharmaceutical formulations can be hard gelatine capsules or tablets and are suitable for use in the prevention and treatment of disorders related to abnormal gastric acid secretion.
Claims (24)
1. A pellet comprising an acid labile benzimidazole compound, wherein the pellet comprises:
(a) an inert nucleus;
(b) a layer disposed over said inert nucleus (a), comprising an acid labile benzimidazole compound, an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients;
(c) one or more intermediate layers that comprise:
(i) an inert, non-alkaline coating, formed of an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients; and (ii) a system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water;
said intermediate layer(s) (c) disposed over said layer (b) that covers the inert nucleus; and (d) an external layer comprising an enteric coating disposed over said intermediate layers) (c).
(a) an inert nucleus;
(b) a layer disposed over said inert nucleus (a), comprising an acid labile benzimidazole compound, an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients;
(c) one or more intermediate layers that comprise:
(i) an inert, non-alkaline coating, formed of an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients; and (ii) a system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water;
said intermediate layer(s) (c) disposed over said layer (b) that covers the inert nucleus; and (d) an external layer comprising an enteric coating disposed over said intermediate layers) (c).
2. A pellet according to claim 1, in which said intermediate layers (c) comprise one or more layers of an inert, non-alkaline coating and one or more layers of a system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water.
3. A pellet according to claim 1 wherein, the inert, non-alkaline coating, formed of an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients, and the system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water, are mixed in a single layer.
4. A pellet according to claim 1, in which said intermediate layers (c) comprise a mixture of one or more layers of inert, non-alkaline coating, and one or more layers of said system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water, and one or more layers of a mixture of inert, non-alkaline coating, and said system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water.
5. A pellet according to claim 1 wherein the inert, non-alkaline coating, formed of an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients is disposed over the layer (b); the layer comprising the system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water is disposed over the layer of the inert, non-alkaline coating; and the layer (d) is disposed over the layer formed by the system of modified release comprising an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water.
6. A pellet according to claim 1 wherein said acid labile benzimidazole compound is a compound of formula (I) wherein R1 is hydrogen, methoxy or difluoromethoxy, R2 is methyl or methoxy, R3 is methoxy, 2,2,2-trifluoroethoxy or 3-methoxypropoxy, and R4 is hydrogen or methyl.
7. A pellet according to claim 1 wherein said acid labile benzimidazole compound is selected from the group consisting of omeprazole, lansoprazole and pantoprazole.
8. A pellet according to claim 1 wherein, said inert, non-alkaline polymer soluble in water, present in the layer (b) is selected from hydroxypropylmethylcellulose (HPMC) and hydroxypropylcellulose (HPC).
9. A pellet according to claim 1 wherein, said inert, non-alkaline polymer soluble in water of the inert, non-alkaline coating, present in the intermediate layer(s) (c) is hydroxypropylmethylcellulose (HMPC).
10. A pellet according to claim 1 wherein, said inert, non-alkaline polymer soluble in water of the system of modified release, present in the intermediate layer(s) (c) is hydroxypropylmethylcellulose (HMPC).
11. A pellet according to claim 1 wherein, said inert, non-alkaline polymer insoluble in water of the system of modified release, present in the intermediate layer(s) (c) is ethylcellulose or a copolymer of ammonium methacrylate.
12. A pellet according to claim 1 wherein, said external layer (d) comprises a gastro-resistant polymer, a plasticizer and one or more pharmaceutically acceptable inert excipients.
13. A method for obtaining a gastro-resistant pellet of modified release that contains as an active ingredient an acid labile benzimidazole compound, that comprises:
(i) applying an aqueous suspension of an acid labile benzimidazole compound, an inert, non-alkaline polymer soluble in water, and one or more pharmaceutically acceptable inert excipients to cover an inert nucleus;
(ii) applying one or more intermediate layers, separated or mixed among themselves that contain (i) an inert, non-alkaline coating, formed of an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients;
and (ii) a system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water, separated or mixed; and (iii) covering said intermediate layer or layers with an aqueous suspension that comprises a gastro-resistant polymer, a plasticizer and one or more pharmaceutically acceptable inert excipients to create an external layer of enteric coating.
(i) applying an aqueous suspension of an acid labile benzimidazole compound, an inert, non-alkaline polymer soluble in water, and one or more pharmaceutically acceptable inert excipients to cover an inert nucleus;
(ii) applying one or more intermediate layers, separated or mixed among themselves that contain (i) an inert, non-alkaline coating, formed of an inert, non-alkaline polymer soluble in water and one or more pharmaceutically acceptable inert excipients;
and (ii) a system of modified release that comprises an inert, non-alkaline polymer soluble in water and an inert, non-alkaline polymer insoluble in water, separated or mixed; and (iii) covering said intermediate layer or layers with an aqueous suspension that comprises a gastro-resistant polymer, a plasticizer and one or more pharmaceutically acceptable inert excipients to create an external layer of enteric coating.
14. A method according to claim 13 wherein said acid labile benzimidazole compound is a compound of formula (I) wherein R1 is hydrogen, methoxy or difluoromethoxy, R2 is methyl or methoxy, R3 is methoxy, 2,2,2-trifluoroethoxy or 3-methoxypropoxy, and R4 is hydrogen or methyl.
15. A method according to claim 13 wherein said acid labile benzimidazole compound is selected from the group consisting of omeprazole, lansoprazole and pantoprazole.
16. A method according to claim 13 wherein, said inert, non-alkaline polymer soluble in water, present in the suspension applied in step (i) is selected from hydroxypropylmethylcellulose (HPMC) and hydroxypropylcellulose (HPC).
17. A method according to claim 13 wherein, said inert, non-alkaline polymer soluble in water, comprised in the inert, non-alkaline coating, present in the suspension applied in step (ii) is hydroxypropylmethylcellulose (HMPC).
18. A method according to claim 13 wherein, said inert, non-alkaline polymer soluble in water, comprised in the system of modified release, present in the suspension applied in step (ii) is hydroxypropylmethylcellulose (HMPC).
19. A method according to claim 13 wherein, said inert, non-alkaline polymer insoluble in water, comprised in the system of modified release, present in the suspension applied in step (ii) is ethylcellulose or a copolymer of ammonium methacrylate.
20. A composition of modified release that comprises one or more pellets of claim 1.
21. A composition according to claim 20, in which one or more of the pellets have the same release profile of the benzimidazole.
22. A composition according to claim 20, in which one or more of the pellets have a different release profile of the benzimidazole.
23. A composition according to claim 20, comprising a mixture of (i) pellets with a quick release profile and (ii) pellets with a slow release profile, in a ratio (i):(ii), by weight, lying between 10:90 and 90:10.
24. A composition according to claim 20, in the form of a capsule or a tablet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009902027A ES2168043B1 (en) | 1999-09-13 | 1999-09-13 | PHARMACEUTICAL FORM ORAL SOLID MODIFIED RELEASE CONTAINING A COMPOSITE OF BENCIMIDAZOL LABIL IN THE MIDDLE ACID. |
ES9902027 | 2000-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2318008A1 true CA2318008A1 (en) | 2001-03-13 |
CA2318008C CA2318008C (en) | 2010-08-17 |
Family
ID=8309905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2318008A Expired - Fee Related CA2318008C (en) | 1999-09-13 | 2000-09-12 | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound |
Country Status (12)
Country | Link |
---|---|
US (1) | US6780436B1 (en) |
EP (1) | EP1086694B1 (en) |
JP (1) | JP4885347B2 (en) |
KR (1) | KR100724201B1 (en) |
AT (1) | ATE334679T1 (en) |
AU (1) | AU777322B2 (en) |
CA (1) | CA2318008C (en) |
CY (1) | CY1106219T1 (en) |
DE (1) | DE60029712T2 (en) |
DK (1) | DK1086694T3 (en) |
ES (2) | ES2168043B1 (en) |
PT (1) | PT1086694E (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
ES2198195B1 (en) * | 2001-12-18 | 2004-10-01 | Laboratorios Del Dr. Esteve, S.A. | COMPRESSED ORAL PHARMACEUTICAL DOSAGE FORM, WITH ENTERIC COATING, CONTAINING A LABIL BENCIMIDAZOL COMPOUND IN THE MIDDLE ACID. |
WO2003084517A2 (en) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Oral suspension of amoxicillin capsules |
PT1492511E (en) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
CA2771725C (en) * | 2002-10-16 | 2015-08-18 | Takeda Pharmaceutical Company Limited | Solid preparation comprising a non-toxic base and a proton pump inhibitor |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
AU2003245033A1 (en) * | 2003-05-08 | 2004-11-26 | Podili Khadgapathi | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation |
US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
WO2005034924A1 (en) * | 2003-10-14 | 2005-04-21 | Natco Pharma Limited | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation |
FR2861990B1 (en) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | LOW DOSAGE TABLETS WITH POLYMER NETWORK |
EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
AR052225A1 (en) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | FORMULATIONS OF MODIFIED RELEASE TABLETS FOR INHIBITORS OF THE PUMP OF PROTONS |
AR051654A1 (en) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | NEW FORMULATIONS OF MODIFIED RELEASE PELLETS FOR PROTON PUMP INHIBITORS |
US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
WO2006111853A2 (en) * | 2005-04-18 | 2006-10-26 | Aurobindo Pharma Limited | Stable solid dosage forms of acid labile drug |
JP5118962B2 (en) * | 2005-04-28 | 2013-01-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Stabilizing composition |
US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
ES2374158T3 (en) * | 2006-07-10 | 2012-02-14 | Dr. R. Pfleger Chemische Fabrik Gmbh | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE IN THE SMALL INTESTINE AND PROCEDURE FOR PREPARATION. |
EP2319504A1 (en) | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
PL2773348T3 (en) * | 2011-11-02 | 2018-07-31 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical composition of omeprazole |
WO2013111149A1 (en) * | 2011-12-21 | 2013-08-01 | Hetero Research Foundation | Controlled release solid oral compositions of dexlansoprazole |
CN103202820B (en) * | 2012-01-11 | 2016-03-30 | 浙江亚太药业股份有限公司 | A kind of stable lansoprazole intestine dissolving capsule and preparation method thereof |
CN104586809A (en) * | 2015-01-08 | 2015-05-06 | 浙江亚太药业股份有限公司 | Esomeprazole magnesium enteric pill coated tablet and preparation method thereof |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
EP3512530B1 (en) * | 2016-09-15 | 2020-11-18 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Oral pyrophosphate for use in reducing tissue calcification |
US20200163895A1 (en) * | 2017-05-17 | 2020-05-28 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB829055A (en) | 1958-02-07 | 1960-02-24 | Charles E Frosst And Company | Improvements in or relating to pharmaceutical preparations |
US4150111A (en) | 1974-05-28 | 1979-04-17 | Allister Warren | Enteric coated magnesium chloride |
JPS5837285B2 (en) | 1975-05-29 | 1983-08-15 | カブシキガイシヤ ミドリジユウジ | It is very difficult to understand the situation. |
JPS5598120A (en) | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
US4470980A (en) | 1980-03-07 | 1984-09-11 | Interx Research Corp. | Method of increasing oral absorption of β-lactam antibiotics |
JPS57208155A (en) | 1981-06-17 | 1982-12-21 | Toshiba Corp | Detecting method for pinhole |
US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
JPS59193831A (en) | 1983-04-18 | 1984-11-02 | Sankyo Co Ltd | Preparation of enteric drug |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPH0774166B2 (en) * | 1987-02-06 | 1995-08-09 | 信越化学工業株式会社 | Method for producing sustained-release coated drug |
JPH0768125B2 (en) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | Oral formulation of acid labile compounds |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
GB8913889D0 (en) * | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
US5395611A (en) | 1990-04-24 | 1995-03-07 | The Governors Of The University Of Alberta | Phenolic amine depigmenting and antimelanoma agents |
US5232706A (en) | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
GB2256587A (en) * | 1991-06-11 | 1992-12-16 | American Cyanamid Co | Acetazolamide in sustained release form |
YU48263B (en) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT |
ATE156707T1 (en) * | 1991-06-21 | 1997-08-15 | Ilsan Ilac Ve Hammaddeleri San | NEW GALENIC PROCESS FOR PELLETS CONTAINING OMEPRAZOLE |
JPH05255088A (en) * | 1991-11-05 | 1993-10-05 | Yoshitomi Pharmaceut Ind Ltd | Pharmaceutical preparation containing antiulcer agent |
JPH05194225A (en) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | Stabilized antiulcer agent-containing preparation |
WO1995003052A1 (en) * | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
EE03305B1 (en) | 1994-07-08 | 2000-12-15 | Astra Aktiebolag | Multiparticulate tableted dosage form I |
SE9402431D0 (en) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
ES2094694B1 (en) | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING. |
US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
DE69631834T2 (en) * | 1995-09-21 | 2005-02-10 | Pharma Pass Ii Llc, Irvine | NEW ACIDIC BENZIMIDAZOLE-CONTAINING MEANS AND METHOD FOR THE PRODUCTION THEREOF |
SE9603667D0 (en) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
JP2762998B2 (en) * | 1997-04-25 | 1998-06-11 | 武田薬品工業株式会社 | Stabilizer for pharmaceutical solid composition and stabilization method |
GB9710800D0 (en) | 1997-05-23 | 1997-07-23 | Cipla Limited | Pharmaceutical composition and method of preparing it |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
SE9702000D0 (en) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
SE9702533D0 (en) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
CA2290969C (en) * | 1997-07-01 | 2004-02-17 | Pfizer Products Inc. | Delayed-release dosage forms of sertraline |
SI9700186B (en) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical preparation with controlled release of active healing substances |
US5965167A (en) * | 1997-10-07 | 1999-10-12 | Sanghvi; Pradeepkumar P. | Dosage units |
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
DK173431B1 (en) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Pharmaceutical formulation comprising a 2 - [[(2-pyridinyl) methyl] sulfinyl] benzimidazole with anti-ulcer activity and progress |
ZA9810765B (en) | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
US6166213A (en) | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
SE9803772D0 (en) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
-
1999
- 1999-09-13 ES ES009902027A patent/ES2168043B1/en not_active Expired - Fee Related
-
2000
- 2000-09-12 US US09/660,022 patent/US6780436B1/en not_active Expired - Lifetime
- 2000-09-12 CA CA2318008A patent/CA2318008C/en not_active Expired - Fee Related
- 2000-09-12 AU AU57919/00A patent/AU777322B2/en not_active Ceased
- 2000-09-13 PT PT00500203T patent/PT1086694E/en unknown
- 2000-09-13 DE DE60029712T patent/DE60029712T2/en not_active Expired - Lifetime
- 2000-09-13 ES ES00500203T patent/ES2269088T3/en not_active Expired - Lifetime
- 2000-09-13 DK DK00500203T patent/DK1086694T3/en active
- 2000-09-13 JP JP2000277838A patent/JP4885347B2/en not_active Expired - Fee Related
- 2000-09-13 AT AT00500203T patent/ATE334679T1/en active
- 2000-09-13 EP EP00500203A patent/EP1086694B1/en not_active Expired - Lifetime
- 2000-09-14 KR KR1020000053939A patent/KR100724201B1/en not_active IP Right Cessation
-
2006
- 2006-10-25 CY CY20061101540T patent/CY1106219T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE334679T1 (en) | 2006-08-15 |
DK1086694T3 (en) | 2006-12-04 |
EP1086694A3 (en) | 2002-09-25 |
JP2001199878A (en) | 2001-07-24 |
JP4885347B2 (en) | 2012-02-29 |
AU5791900A (en) | 2001-03-15 |
DE60029712T2 (en) | 2007-08-02 |
CA2318008C (en) | 2010-08-17 |
EP1086694A2 (en) | 2001-03-28 |
PT1086694E (en) | 2006-12-29 |
EP1086694B1 (en) | 2006-08-02 |
US6780436B1 (en) | 2004-08-24 |
AU777322B2 (en) | 2004-10-14 |
ES2168043A1 (en) | 2002-05-16 |
CY1106219T1 (en) | 2011-06-08 |
KR100724201B1 (en) | 2007-05-31 |
DE60029712D1 (en) | 2006-09-14 |
ES2269088T3 (en) | 2007-04-01 |
KR20020020974A (en) | 2002-03-18 |
ES2168043B1 (en) | 2003-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2318008A1 (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
EP1078628B1 (en) | Multiple unit tableted dosage form | |
RU2166935C2 (en) | Tabletted multiunit medicinal form, method of its preparing, method of inhibition of gastric acid secretion or treatment of mammals and humans with gastroenteric diseases | |
EP2112920B1 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
AU713242B2 (en) | Novel composition containing an acid-labile omeprazole and process for its preparation | |
ES2244167T3 (en) | NEW STABLE MULTIUNITARY PHARMACEUTICAL PREPARATIONS CONTAINING SUBSTITUTED BENCIMIDAZOLS. | |
US6610323B1 (en) | Oral pharmaceutical pulsed release dosage form | |
AU2006242067B2 (en) | Stabilized composition | |
US20050214371A1 (en) | Stable pharmaceutical composition comprising an acid labile drug | |
NO319999B1 (en) | Tabulated effervescent multiple unit dosage forms comprising a proton pump inhibitor, method of preparing such dosage forms, and use thereof. | |
EP2319504A1 (en) | Pharmaceutical solid dosage form | |
CA2470609C (en) | Tableted oral pharmaceutical dosage form, with an enteric coating, containing a benzimidazole compound labile in an acid medium | |
US20240033224A1 (en) | Enteric-coated pellet, method for preparing same and formulation comprising same | |
RU2161481C2 (en) | Novel composition containing acid-nonstable omeprazole and method of its preparing | |
AU745707B2 (en) | novel composition containing an acid-labile omeprazole and process for its preparation | |
SK50512010A3 (en) | Formulation of omeprazole free of HPC / HPMC |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150914 |